Microdosing, the repeated use of psychedelic substances at low doses, is growing in popularity among recreational consumers. While this practice is associated with many benefits to mood, well-being and health, research in this area is in its early stages and predominantly centered on human applications. In this narrative review, we synthesize the findings from studies investigating the effects...
O psicodélico clássico ayahuasca, e a substância rapé, também utilizadas em rituais xamânicos com o uso da ayahuasca, eliciam estados de consciência podendo alterar a percepção temporal dos seres humanos. Estudos envolvendo tarefas de reprodução do tempo e psicodélicos clássicos mostram que estas substâncias alteram a percepção temporal em estímulos superiores a 1,6 segundos. A literatura...
There has been a recent resurgence in research on psychedelics as therapeutic agents for psychiatric conditions. This leading article outlines the studies to date of classic psychedelic treatments for treatment-resistant depression and major depression, including psilocybin, ayahuasca, dimethyltryptamine (DMT), and O-methyl-bufotenine (5-Me-O DMT). We discuss the potential of expanding...
Serotonin 5-HT2A receptors were one of the first serotonin receptors to be pharmacologically characterized. In mammals, they are expressed throughout the body in nearly every cell and tissue type, with the highest density in cortical layer V of the brain. They are involved in several aspects of normal physiological processes and behaviors and have been implicated in the etiology of...
Improved outcomes for substance use disorders have been described following non-clinical (“naturalistic”) psychedelic use. This exploratory study aimed to describe the naturalistic psychedelic experiences of people with substance use concerns and their reported needs and perceived utility of psychosocial support following naturalistic psychedelic use to integrate experiences and achieve...
Objective: Prior research has found an association between psychedelic use and reduced stigma attached to mental illness. However, whether psychedelics alleviate stigma-related distress remains unclear. Since stigma impacts different groups uniquely, any moderating effect of psychedelics on stigma-related distress is likely to vary across subpopulations. This study addresses two main questions:...
Abstract 5-MeO-DMT, a potent, short-acting psychedelic, induces profound shifts in cognition, affect, and self-awareness. Because language explicitly expresses these domains and voice implicitly conveys them, both may serve as potential ‘biomarkers’ of behavioural change. This study introduces a novel framework for analysing baseline language and vocal features, pre- to post-psychedelic...
New synthetic tryptamine derivatives have emerged in the underground market. They act on serotonin receptors mimicking the effects of hallucinogenic drugs such as DOM. The DEA has identified three tryptamine derivatives of concern, 5-MeO-DBT, 5-Cl-DMT, and 4-OH-MiPT. Swiss Webster mice were tested for locomotor activity. Discriminative stimulus effects were tested in male Sprague-Dawley rats...
European PsychiatryApril 1, 2025E. E. Morales Castellano, P. Rivero Rodríguez, Marina Martínez Grimal et al.
Introduction The relationship between psychosis and ayahuasca use is a topic of considerable interest and debate in the scientific and medical community. Ayahuasca is traditionally used in shamanic ceremonies in the Amazon, composed mainly of the Banisteriopsis caapi vine and the leaves of Psychotria viridis, which contain DMT (dimethyltryptamine), a powerful hallucinogen. Ayahuasca induces...
Introduction Persons with schizophrenia are currently excluded from psychedelic-assisted therapy due to concerns about psychedelic-induced acute or persistent psychotic symptoms. However, meta-analytic evidence of the precise risk for psychedelic-induced de novo and exacerbation of psychosis in people with pre-existing psychotic disorders is lacking. Objectives We conducted an overview of...